N-glycosylation Regulates Intrinsic IFN-γ Resistance in Colorectal Cancer: Implications for Immunotherapy.
Colon Cancer
IFNGR1
Immune Evasion
Journal
Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
09
03
2022
revised:
07
11
2022
accepted:
08
11
2022
pubmed:
20
11
2022
medline:
3
3
2023
entrez:
19
11
2022
Statut:
ppublish
Résumé
Advanced colorectal carcinoma (CRC) is characterized by a high frequency of primary immune evasion and refractoriness to immunotherapy. Given the importance of interferon (IFN)-γ in CRC immunosurveillance, we investigated whether and how acquired IFN-γ resistance in tumor cells would promote tumor growth, and whether IFN-γ sensitivity could be restored. Spontaneous and colitis-associated CRC development was induced in mice with a specific IFN-γ pathway inhibition in intestinal epithelial cells. The influence of IFN-γ pathway gene status and expression on survival was assessed in patients with CRC. The mechanisms underlying IFN-γ resistance were investigated in CRC cell lines. The conditional knockout of the IFN-γ receptor in intestinal epithelial cells enhanced spontaneous and colitis-associated colon tumorigenesis in mice, and the loss of IFN-γ receptor α (IFNγRα) expression by tumor cells predicted poor prognosis in patients with CRC. IFNγRα expression was repressed in human CRC cells through changes in N-glycosylation, which decreased protein stability via proteasome-dependent degradation, inhibiting IFNγR-signaling. Downregulation of the bisecting N-acetylglucosaminyltransferase III (MGAT3) expression was associated with IFN-γ resistance in all IFN-γ-resistant cells, and highly correlated with low IFNγRα expression in CRC tissues. Both ectopic and pharmacological reconstitution of MGAT3 expression with all-trans retinoic acid increased bisecting N-glycosylation, as well as IFNγRα protein stability and signaling. Together, our results demonstrated that tumor-associated changes in N-glycosylation destabilize IFNγRα, causing IFN-γ resistance in CRC. IFN-γ sensitivity could be reestablished through the increase in MGAT3 expression, notably via all-trans retinoic acid treatment, providing new prospects for the treatment of immune-resistant CRC.
Sections du résumé
BACKGROUND & AIMS
Advanced colorectal carcinoma (CRC) is characterized by a high frequency of primary immune evasion and refractoriness to immunotherapy. Given the importance of interferon (IFN)-γ in CRC immunosurveillance, we investigated whether and how acquired IFN-γ resistance in tumor cells would promote tumor growth, and whether IFN-γ sensitivity could be restored.
METHODS
Spontaneous and colitis-associated CRC development was induced in mice with a specific IFN-γ pathway inhibition in intestinal epithelial cells. The influence of IFN-γ pathway gene status and expression on survival was assessed in patients with CRC. The mechanisms underlying IFN-γ resistance were investigated in CRC cell lines.
RESULTS
The conditional knockout of the IFN-γ receptor in intestinal epithelial cells enhanced spontaneous and colitis-associated colon tumorigenesis in mice, and the loss of IFN-γ receptor α (IFNγRα) expression by tumor cells predicted poor prognosis in patients with CRC. IFNγRα expression was repressed in human CRC cells through changes in N-glycosylation, which decreased protein stability via proteasome-dependent degradation, inhibiting IFNγR-signaling. Downregulation of the bisecting N-acetylglucosaminyltransferase III (MGAT3) expression was associated with IFN-γ resistance in all IFN-γ-resistant cells, and highly correlated with low IFNγRα expression in CRC tissues. Both ectopic and pharmacological reconstitution of MGAT3 expression with all-trans retinoic acid increased bisecting N-glycosylation, as well as IFNγRα protein stability and signaling.
CONCLUSIONS
Together, our results demonstrated that tumor-associated changes in N-glycosylation destabilize IFNγRα, causing IFN-γ resistance in CRC. IFN-γ sensitivity could be reestablished through the increase in MGAT3 expression, notably via all-trans retinoic acid treatment, providing new prospects for the treatment of immune-resistant CRC.
Identifiants
pubmed: 36402190
pii: S0016-5085(22)01294-X
doi: 10.1053/j.gastro.2022.11.018
pmc: PMC10009756
mid: NIHMS1851134
pii:
doi:
Substances chimiques
Interferon-gamma
82115-62-6
Tretinoin
5688UTC01R
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
392-406.e5Subventions
Organisme : NCI NIH HHS
ID : R01 CA218133
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA227629
Pays : United States
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Cancer Res. 1985 Aug;45(8):3503-9
pubmed: 3160456
Nat Rev Immunol. 2006 Nov;6(11):836-48
pubmed: 17063185
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Nat Commun. 2016 Aug 30;7:12632
pubmed: 27572267
Anticancer Res. 2012 May;32(5):1565-72
pubmed: 22593433
Mol Cell Proteomics. 2012 Sep;11(9):571-85
pubmed: 22573871
J Biol Chem. 1990 Jan 25;265(3):1710-7
pubmed: 2136857
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Glycobiology. 2005 Jan;15(1):43-53
pubmed: 15329358
Biochem J. 2017 Oct 10;474(20):3543-3557
pubmed: 28883123
J Immunol. 2000 Apr 1;164(7):3506-11
pubmed: 10725704
Int J Cancer. 2008 Nov 1;123(9):2120-9
pubmed: 18697200
Front Immunol. 2013 Sep 03;4:267
pubmed: 24027571
Cancer Chemother Pharmacol. 2004 Mar;53(3):253-60
pubmed: 14648016
Sci Transl Med. 2016 Feb 24;8(327):327ra26
pubmed: 26912905
Science. 2004 Oct 1;306(5693):120-4
pubmed: 15459394
Science. 2019 May 3;364(6439):485-491
pubmed: 31048490
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Genome Med. 2017 May 24;9(1):46
pubmed: 28539123
Histochem Cell Biol. 2012 Aug;138(2):339-50
pubmed: 22565205
Nat Cancer. 2020 Mar;1(3):291-301
pubmed: 32566933
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Biomedicine (Taipei). 2014;4:22
pubmed: 25520935
PLoS One. 2017 Nov 9;12(11):e0176181
pubmed: 29121062
Oncol Rep. 1996 May;3(3):447-51
pubmed: 21594390
Oncology. 1996 Mar-Apr;53(2):159-62
pubmed: 8604243
J Biol Chem. 2012 May 11;287(20):16563-74
pubmed: 22451656
Cancer Discov. 2017 Feb;7(2):188-201
pubmed: 27903500
Cell. 2016 Aug 11;166(4):920-934
pubmed: 27499022
Glycoconj J. 2012 Dec;29(8-9):609-18
pubmed: 22476631
Oncotarget. 2016 Jul 5;7(27):42099-42109
pubmed: 27286456
Eur J Cancer. 2013 Jun;49(9):2233-42
pubmed: 23478000
Cancer Res. 2006 Sep 15;66(18):9299-307
pubmed: 16982775
J Biol Chem. 1989 Jul 15;264(20):11981-8
pubmed: 2526123
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Nat Immunol. 2019 Dec;20(12):1574-1583
pubmed: 31745335
Mol Cancer. 2017 Jul 6;16(1):116
pubmed: 28683746
J Pharmacol Exp Ther. 2021 Jan;376(1):21-28
pubmed: 33158943
Carcinogenesis. 2013 Jan;34(1):153-62
pubmed: 23042300
Nat Cancer. 2020 Mar;1(3):302-314
pubmed: 32803171
Int J Mol Sci. 2018 Feb 15;19(2):
pubmed: 29462882
Cancer Discov. 2021 Jul;11(7):1826-1843
pubmed: 33627378
Int Immunopharmacol. 2018 Oct;63:282-291
pubmed: 30121453
PLoS One. 2012;7(12):e52975
pubmed: 23300837
Gut. 2010 Jul;59(7):926-33
pubmed: 20581241